Experience with Subcutaneous Versus Intravenous Administration of Erythropoietin in Haemodialysis Patients

  • K. W. Dreyling
  • K. Ehlen
  • P. Schollmeyer
  • W. H. Hörl
Conference paper

Abstract

The efficacy of recombinant human erythropoietin (rhEPO) in correcting the anaemia in patients with end-stage renal failure has been demonstrated in several clinical studies [1, 6, 9, 18, 19]. In these studies rhEPO was given intravenously. The optimal route of rhEPO administration has not been clearly established. In the study of MacDougall and coworkers in patients on continuous ambulatory peritoneal dialysis identical rhEPO doses were administered intravenously (i. v.) and subcutaneously (s. c.). Peak levels and bioavailability of s. c. rhEPO are lower than those of i. v. rhEPO [13]. Bommer et al. [3] reported s. c. administration of rhEPO to be effective at a smaller weekly dose than i. v. rhEPO. Similar results have been published by Zehnder and Blumberg [20]. However, these findings were challenged [14].

Keywords

Burning Creatinine Heparin Tuberculosis Anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bommer J, Alexiou C, Müller-Bühl U, Eifert J, Ritz E (1987) Recombinant human erythropoietin therapy in haemodialysis patients-dose determination and clinical experience. Nephrol Dial Transplant 2: 238–242PubMedGoogle Scholar
  2. 2.
    Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P (1988) Dose-related effects of recombinant human erythropoietin on erythropoiesis. Contrib Nephrol 66: 85–93PubMedGoogle Scholar
  3. 3.
    Bommer J, Ritz E, Weinreich T, Bommer G, Ziegler T (1988) Subcutaneous erythropoietin. Lancet 1: 406CrossRefGoogle Scholar
  4. 4.
    Bommer J, Weinreich T, Ritz E, Zeier M, Bommer G (1989) Efficacy of subcutaneous or intravenous recombinant human erythropoietin therapy in dialysis patients. Nephrol Dial Transplant 4: 471AGoogle Scholar
  5. 5.
    Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300: 573–578CrossRefGoogle Scholar
  6. 6.
    Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C (1987) Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 295: 1017–1020CrossRefGoogle Scholar
  7. 7.
    Dreyling KW, Steinhauer HB, Geiger H, Hörl WH, Schollmeyer P (1989) Platelet function under recombinant human erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 4: 472AGoogle Scholar
  8. 8.
    Edmunds ME, Walls J, Tucker B, Baker LRI,Tomson CRV,Ward M, Cunningham J, Moore R, Winearls CG (1989) Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 4: 1065–1069Google Scholar
  9. 9.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73–78PubMedCrossRefGoogle Scholar
  10. 10.
    Granolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S (1989) Experience with daily self-administrated subcutaneous erythropoietin. Contrib Nephrol 76: 143–148PubMedGoogle Scholar
  11. 11.
    Grützmacher P, Bergmann M,WeinreichT, Nattermann U, Reimers E, Pollok M (1988) Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol 66: 104–113Google Scholar
  12. 12.
    Kampf D, Kahl A, Passlik J, Pustelnik A, Eckardt K-U, Ehmer B, Jacobs C, Baumelou A, Grabensee B, Gahl GM (1989) Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Contrib Nephrol 76: 106–111PubMedGoogle Scholar
  13. 13.
    MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1: 425–427PubMedCrossRefGoogle Scholar
  14. 14.
    Meisl F, Manker W, Loibl U, Buxbaum M, Stockenhuber F, Steinbach K (1990) No therapeutic or economic advantage of erythropoietin application by the subcutaneous route. 11th International Congress of Nephrology, Tokyo, 202AGoogle Scholar
  15. 15.
    Moia M, Vizzotto L, Cattaneo M, Mannucci PM, Casati S, Ponticelli C (1987) Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 2: 1227–1229PubMedCrossRefGoogle Scholar
  16. 16.
    Raine AEG (1990) Seizures and hypertension events. Semin Nephrol 10(2) [Suppl l]: 40–50Google Scholar
  17. 17.
    Samtleben W, Baldamus CA, Bommer J, Grützmacher P, Nonnast-Daniel B, Scigalla P, Gurland HJ (1989) Indications and contraindications for recombinant human erythropoietin treatment. Contrib Nephrol 76: 193–200PubMedGoogle Scholar
  18. 18.
    Sundal E, Kaeser U (1989) Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year’s treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 4: 979–987PubMedGoogle Scholar
  19. 19.
    Winearls CG, Pippard MJ, Downing MR, Oliver DO, Reid C, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1176–1179Google Scholar
  20. 20.
    Zehnder C, Blumberg A (1991) Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration. Nephron 57: 485–486PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • K. W. Dreyling
  • K. Ehlen
  • P. Schollmeyer
  • W. H. Hörl

There are no affiliations available

Personalised recommendations